EUCTR2008-008394-63-IT进行中（未招募）不适用
A 52-week treatment, randomized, double-blind, placebo-controlled, with open label tiotropium, parallelgroupstudy to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructivepulmonary disease - ND
ovartis Pharma Service AG0 个研究点目标入组 1,065 人开始时间: 2009年10月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,065
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female adults aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any
- •study-related procedure.
- •2. Patients with moderate to severe stable COPD (Stage II or Stage III) according to the (GOLD Guidelines
- •3. Current or ex-smokers who have a smoking history of at least 10 pack years. (Ten pack-years are defined as 20
- •cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.)
- •4. Patients with a post-bronchodilator FEV1 ≥30% and < 80% of the predicted normal, and post-bronchodilator
- •FEV1/FVC < 0.7 at Visit 2 (day -14)
- •5. Patients, according to daily electronic diary data between Visit 2 (-14) and Visit 3 (day 1), with a total score of
- •1 or more on at least 4 of the last 7 days prior to Visit 3 (For scoring information see Section 7.4.3.1.)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant women or nursing mothers
- •2. Women of child-bearing potential, as defined in the protocol
- •3. Patients requiring long term oxygen therapy (> 15 h a day) on a daily basis for chronic hypoxemia, or who
- •have been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to Visit 1 or between
- •Visit 1 (day -21) and Visit 3 (day 1).
- •4. Patients who have had a lower respiratory tract infection within 6 weeks prior to Visit 1 (day -21). Patients who
- •develop a lower respiratory tract infection or COPD exacerbation during the screening period (up to Visit 3 (day
- •1)) will not be eligible, but will be permitted to be re-screened at a later date (at least 6 weeks after the resolution
- •of the lower respiratory tract infection).
- •5. Patients who, in the judgment of the investigator or the responsible Novartis personnel, have a clinically
- •relevant laboratory abnormality or a clinically significant condition such as (but not limited to):
- •unstable ischemic heart disease, left ventricular failure, history of myocardial infarction, arrhythmia (excluding chronic stable AF)
- •history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years
- •whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell
- •carcinoma of the skin.
- •narrow-angle glaucoma
- •symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment or
- •urinary retention
- •any condition which might compromise patient safety or compliance, interfere with evaluation, or preclude
- •completion of the study
- •6. Patients with any history of asthma indicated by (but not limited to) a blood eosinophil count > 600/mm3 (at
- •visit 1) or onset of symptoms prior to age 40 years.
- •7. Patients with a history of long QT syndrome or whose QTc measured at Visit 1 (day -21) (Fridericia method) is
- •prolonged (>450 ms for males or >470 for females).
- •8. Treatments for COPD and allied conditions: the following medications should not be used between Visits 1
- •(day -21) and 3 (day 1).
- •The minimum washout prior to Visit 2 (Day -14) is specified below. For patients in the Holter monitor sub-group
- •minimum washout is prior to the day before Visit 2 (day -15):
- •The long acting anticholinergic agent tiotropium:7 days.
- •Short acting anticholinergics: 8 h
- •Fixed combinations of β2-agonists and inhaled corticosteroids: 48 hours. (Patients taking fixed combinations of
- •β2-agonists and inhaled corticosteroids must be switched to the equivalent inhaled corticosteroid as monotherapy
- •plus salbutamol/albuterol as rescue therapy at least 48 hours prior to Visit 2)
- •Long-acting β2-agonists: 48 h
- •Short acting β2-agonists (other than those prescribed in the study): 6 h
- •Theophylline (any formulation): 7 days
- •Combinations of inhaled short acting anticholinergics and short acting β2-agonists: 12 hours
- •9. Patients who need the following treatments for COPD and allied conditions unless they have been stabilized
- •as follows:
- •Inhaled corticosteroids, in recommended and constant doses and dose regimens (previously given as part of a
- •fixed dose combination of LABA + ICS) at least one month prior to Visit 1.
- •Intranasal corticosteroids, in recommended and constant doses and dose regimens - at least one month prior to
- •H1 antagonists at least 5 days prior to Visit 1.
- •10. Long term oral prednisone therapy (or equivalent), defined as ≥
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney diseaseType II Diabetes Mellitus and Diabetic Kidney DiseaseMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-000990-11-DEBayer AG9,600
进行中（未招募）
1 期
A study to investigate if inhaled Interferon beta-1a is safe, and could prevent or reduce the severity of asthma attacks when administered to asthma patients at the onset of a virus affecting their airways (e.g. common cold or influenza)AsthmaEUCTR2014-005084-32-GBAstraZeneca AB121
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20mg) multicenter study of long-term glycemic control with rimonabantin treatment-naïve patients with type 2 diabetes - SERENADEPatients with Type 2 diabetes not treated by a pharmacological agent.MedDRA version: 7.0Level: LLTClassification code 10045242EUCTR2004-004881-34-GBSanofi-Synthelabo Recherche264
进行中（未招募）
不适用
Efficacy and safety study of QAW039 in the treatment of patients with moderate to severe atopic dermatitisAtopic dermatitisEUCTR2012-005321-78-DEovartis Pharma Services AG92
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel-group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses - TEMSOEUCTR2004-000555-42-ITsanofi-aventis Recherche & De`veloppement870